MG
DNLI icon

Marex Group’s Denali Therapeutics DNLI Stock Holding History

Marex Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.51M Sell
287,000
-1
-0% -$20 0.03% 210
2025
Q4 		$4.74M Sell
287,001
-3,999
-1% -$67.5K 0.03% 224
2025
Q3 		$4.23M Buy
291,000
+29,000
+11% +$417K 0.03% 203
2025
Q2 		$3.67M Buy
+262,000
New +$3.69M 0.03% 183

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marex Group's DNLI Position: Q1 2026 in Review

Marex Group reduced its Denali Therapeutics (DNLI) stake by 0% in Q1 2026, selling an estimated $20 and leaving 287,000 shares worth $5.51M. The position accounts for 0.03% of the portfolio, ranked #210.

Marex Group first reported a position in DNLI in Q2 2025 and has held it in 4 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Marex Group held 287,000 shares of Denali Therapeutics worth $5.51M as of Q1 2026.
  • Marex Group sold 1 Denali Therapeutics share in Q1 2026, an estimated $20.
  • Denali Therapeutics made up 0.03% of Marex Group's portfolio in Q1 2026, its #210 holding.
  • Marex Group first reported a position in Denali Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.